Evaluation of the quality of life and sexual functioning of women using a 30-μg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive

European Journal of Contraception and Reproductive Health Care

Volumn 13, Issue 1, 2008, Pages 49-57

  Skrzypulec, V ^a   Drosdzol, A ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Drospirenone; Oral contraceptives; Quality of life; Sexual functioning

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DYSPAREUNIA; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MENSTRUAL CYCLE; MENTAL HEALTH; PHYSICAL ACTIVITY; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL AROUSAL; SEXUAL FUNCTION; SMOKING; STRESS;

ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 39449130211     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180701712406     Document Type: Article

References (25)

1. Rekomendacje Polskiego Towarzystwa Ginekologicznego dotycza̧ce antykoncepcji hormonalnej - stan na rok 2006. Rekomendacje Polskiego Towarzystwa Ginekologicznego. Wydanie specjalne. [Polish Gynaecology Society's Recommendations on Hormonal Contraception - 2006. Polish Gynaecology Society's Recommendations. Special Issue]. Ginekologia po Dyplomie 2006:27-31.
2. Yuzpe AA. Oral contraception: trends over time. J Reprod Med 2002;47:967-73.
3. Somma MA. Ethinyl estradiol/drospirenone (Yasmin): A newer oral contraceptive. Am Fam Physician 2004;69:24-5.
4. Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: A review of its use as an oral contraceptive. Treat Endocrinol 2003;2:49-70.
5. Schultz-Zehden B, Boschitsch E. User experience with an oral contraceptive containing ethinylestradiol 30 μg and drospirenone 3 mg (Yasmin) in clinical practice. Treat Endocrinol 2006;5:251-6.
6. Mansour D. Experiences with Yasmin: The acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care 2002;7(Suppl 3):35-41.
7. Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000;5(Suppl 3):34-40.
8. Oelkers W. Drospirenone with combination with estrogens: For contraception and hormone replacement therapy. Climacteric 2005;8(Suppl 3):19-27.
9. Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care 2002;7(Suppl 3):19-26.
10. Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 μg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005;72:19-23.
11. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey: Manual and interpretation guide. Boston: New England Medical Center, Health Institute, 1993.
12. Ware JE, Kosinski M. SF-36 Physical and mental health summary scales: A manual for users of version 1, 2nd edn. Lincoln: Quality Metric Incorporated, 2001.
13. Ware JE. SF-36 Health Survey update. Spine 2000;25:3130-9.
14. Ware JE, Kosinski M, Gandek BG, et al. The factor structure of the SF-36 health survey in 10 countries: Results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 1998;51:1159-65.
15. Turner-Bowker DM, Bartley PJ, Ware JE. SF-36 Health Survey and 'SF' bibliography, 3rd edn. Lincoln: Quality Metric Incorporated, 2002.
16. McHorney CA, Ware JE. Construction and validation of an alternate form general mental health scale for the Medical Outcomes Study Short Form 36-Item Health Survey. Med Care 1995;33:15-28.
17. Jenkinson C. The SF-36 physical and mental health summary measures: An example of how to interpret scores. J Health Serv Res Policy 1998;3:92-6.
18. Rosen R, Brown C, Heinman J, et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
19. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003;29:39-46.
20. Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): Cross-validation and development of clinical cut-off scores. J Sex Marital Ther 2005;31:1-20.
21. Lew-Starowicz Z. Skala SFŻ (Mell-Krat) - SFM. [SFŻ Scale (Mell-Krat) - SFM]. In Lew-Starowicz Z, ed., Seksuologia sa̧dowa. [Forensic sexology]. Warszawa: PZWL 2000. 380-7.
22. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003;8:37-51.
23. Bitzer J, Tschudin S, Meier-Burgoa J, et al. Effects on the quality of life of a new oral contraceptive containing 30 mcg EE and 3 mg drospirenone (Yasmin). Schweiz Rundsch Med Prax 2003;92:1177-84.
24. Mansour D. The non-contraceptive benefits and acceptability of Yasmin®. Eur J Contracept Reprod Health Care 2004;9(Suppl 1):194.
25. Sillem M. Yasmin® and the extended regimen: current experience. Eur J Contracept Reprod Health Care 2004;9(Suppl 1):194.